Home> Products> flexible dosing regimens

{ "products": [ { "_id": "6954d5cbb4697f18294b1c0e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Dydrogesterone 10 mg", "description": "DABROSTON 10 is a pharmaceutical preparation containing Dydrogesterone 10 mg, a synthetic progestogen that closely mimics the natural hormone progesterone produced by the female body. Manufactured with precision and care, DABROSTON 10 represents a breakthrough in women's reproductive health management, offering a reliable and effective solution for various gynecological conditions related to progesterone deficiency.\nUnlike many other synthetic progestogens, Dydrogesterone in DABROSTON 10 has a unique molecular structure that allows it to work specifically on the uterine lining without causing unwanted androgenic or estrogenic effects. This makes it an ideal choice for women requiring hormonal support while minimizing the risk of side effects commonly associated with other progestational agents.\nDABROSTON 10 is prescribed by healthcare professionals worldwide for conditions ranging from menstrual irregularities to fertility support, endometriosis management, and prevention of miscarriage in women with a history of recurrent pregnancy loss. Its versatility and safety profile have made it a cornerstone in modern gynecological therapeutics.\nUnderstanding Dydrogesterone and Its Uses\nDydrogesterone is an orally active progestogen that was specifically developed to provide the benefits of natural progesterone without the drawbacks of traditional synthetic progestogens. When you take DABROSTON 10, the Dydrogesterone is absorbed into your bloodstream and acts on progesterone receptors throughout your body, particularly in the uterus, where it exerts its primary therapeutic effects.\nPrimary Uses of DABROSTON 10:\nMenstrual Disorders: DABROSTON 10 is highly effective in treating various menstrual irregularities, including dysmenorrhea (painful periods), irregular menstrual cycles, and secondary amenorrhea (absence of periods). By regulating the endometrial lining, it helps restore normal menstrual patterns and reduces associated discomfort.\nEndometriosis Management: For women suffering from endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, causing pain and fertility issues, DABROSTON 10 helps suppress the growth of endometrial tissue and provides significant symptom relief.\nLuteal Phase Support: During fertility treatments or for women with luteal phase defects, DABROSTON 10 provides crucial progesterone support to help prepare the uterine lining for embryo implantation and maintain early pregnancy.\nPrevention of Miscarriage: Women with a history of recurrent miscarriage due to progesterone deficiency can benefit from DABROSTON 10, which helps maintain the uterine environment necessary for pregnancy continuation.\nPremenstrual Syndrome (PMS): The hormonal imbalances that contribute to PMS symptoms can be effectively managed with DABROSTON 10, providing relief from mood swings, breast tenderness, and bloating.\nHormone Replacement Therapy (HRT): When combined with estrogen therapy in postmenopausal women, DABROSTON 10 protects the uterine lining from excessive growth (endometrial hyperplasia) that estrogen alone might cause.\nDysfunctional Uterine Bleeding: Abnormal uterine bleeding not caused by organic pathology can be controlled with DABROSTON 10 by regulating the endometrial cycle.\nKey Benefits of DABROSTON 10\n1. Natural Hormone Profile\nOne of the most significant advantages of DABROSTON 10 is its molecular similarity to natural progesterone. This means your body recognizes and processes it almost identically to the progesterone it produces naturally, resulting in better tolerance and effectiveness.\n2. Minimal Side Effects\nUnlike many synthetic progestogens that can cause masculinizing effects, weight gain, or mood disturbances, DABROSTON 10 has a remarkably clean side effect profile. It doesn't possess androgenic, estrogenic, or glucocorticoid activity, which means fewer unwanted effects on your body.\n3. Selective Progestational Activity\nDABROSTON 10 works specifically on the uterine lining where it's needed most, without significantly affecting other body systems. This targeted action makes it highly effective for gynecological conditions while maintaining safety.\n4. Oral Administration\nThe convenience of oral dosing makes DABROSTON 10 easy to incorporate into your daily routine. No injections or invasive procedures are required, and the tablets can be taken with or without food.\n5. Pregnancy Safe\nWhen prescribed appropriately, DABROSTON 10 is considered safe during pregnancy, particularly in the first trimester for women at risk of miscarriage. It doesn't harm fetal development and can be crucial in maintaining healthy pregnancies.\n6. Metabolic Neutrality\nDABROSTON 10 doesn't adversely affect lipid metabolism, glucose tolerance, or blood clotting factors in the way some other hormonal preparations might. This makes it suitable for a broader range of women, including those with metabolic concerns.\n7. Flexible Dosing\nThe 10 mg strength allows for flexible dosing regimens tailored to individual needs. Your healthcare provider can adjust the timing and duration of treatment based on your specific condition and response.\n8. Proven Efficacy\nDecades of clinical use and extensive research have established DABROSTON 10 (Dydrogesterone) as a gold standard in progestogen therapy. Its effectiveness has been demonstrated in numerous clinical trials and real-world applications.\n9. Quality of Life Improvement\nBy effectively managing hormonal imbalances and their associated symptoms, DABROSTON 10 significantly improves quality of life. Women report better sleep, improved mood, reduced pain, and enhanced overall well-being.\n10. Supports Fertility Goals\nFor women trying to conceive, DABROSTON 10 provides essential hormonal support that can make the difference between conception success and failure, particularly in cases of luteal phase deficiency or recurrent pregnancy loss.\nUnderstanding Side Effects\nWhile DABROSTON 10 is generally well-tolerated, like all medications, it may cause side effects in some individuals. Understanding these potential effects helps you make informed decisions and know when to contact your healthcare provider.\nCommon and Generally Mild Side Effects:\nHeadache: Some women experience mild to moderate headaches, particularly when first starting treatment. These typically resolve as your body adjusts to the medication.\nNausea: Mild nausea may occur, especially if taken on an empty stomach. Taking DABROSTON 10 with food can help minimize this effect.\nBreast Tenderness: Temporary breast sensitivity or tenderness is relatively common and usually subsides with continued use.\nMood Changes: Mild mood fluctuations may occur, though DABROSTON 10 is less likely to cause mood disturbances compared to other progestogens.\nDizziness: Some women report feeling slightly dizzy, particularly shortly after taking the medication.\nAbdominal Discomfort: Mild stomach discomfort or bloating may occur but is generally temporary.\nLess Common Side Effects:\nBreakthrough bleeding or spotting between periods may occur, especially during the first few cycles of treatment. Fatigue or drowsiness can affect some individuals. Skin reactions such as mild rash or itching are possible but rare. Some women may experience changes in menstrual flow pattern. Rarely, liver function changes may occur, which is why periodic monitoring may be recommended for long-term use.\nWhen to Contact Your Healthcare Provider:\nWhile serious side effects are rare with DABROSTON 10, you should contact your doctor immediately if you experience severe abdominal pain, significant mood changes or depression, jaundice (yellowing of skin or eyes), severe allergic reactions including difficulty breathing or swelling, severe or persistent headaches, visual disturbances, or unusual vaginal bleeding.\nIt's important to remember that most women taking DABROSTON 10 experience few to no side effects. The benefits of treatment typically far outweigh the potential risks, especially when the medication is used as prescribed under medical supervision.\nImportant Considerations\nNot for Everyone: DABROSTON 10 should not be used by women with known hypersensitivity to Dydrogesterone, undiagnosed vaginal bleeding, or certain liver conditions. Always inform your healthcare provider about your complete medical history.\nDrug Interactions: Certain medications may interact with DABROSTON 10, including some enzyme-inducing drugs that can reduce its effectiveness. Inform your doctor about all medications, supplements, and herbal products you're taking.\nPregnancy and Breastfeeding: While DABROSTON 10 is used to support early pregnancy, its use in later pregnancy stages should only be under medical supervision. Small amounts may pass into breast milk, so discuss with your doctor if you're breastfeeding.\nMonitoring: Depending on your condition and duration of treatment, your healthcare provider may recommend periodic check-ups and possibly liver function tests to ensure safe, continued use.\nHow to Use DABROSTON 10\nAlways take DABROSTON 10 exactly as prescribed by your healthcare provider. The dosing regimen varies depending on the condition being treated. It may be taken continuously, cyclically (certain days of your menstrual cycle), or in specific patterns for fertility support. Tablets should be swallowed whole with water and can be taken with or without food. If you miss a dose, take it as soon as you remember unless it's nearly time for your next dose. Never double up doses to make up for a missed one.\nConclusion\nDABROSTON 10 represents a significant advancement in women's reproductive health management, offering a safe, effective, and well-tolerated solution for various gynecological conditions related to progesterone deficiency. Its unique molecular structure, which closely mimics natural progesterone, sets it apart from other synthetic progestogens by providing therapeutic benefits without the unwanted androgenic effects commonly associated with hormonal treatments.", "price": 637.0, "discountamount": 191.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2258, "imageuri": "https://productimages.withfloats.com/actual/6954d5cd5542d9b6b39275fa.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6954d5cd5542d9b6b39275fa.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-31T07:50:35.025Z", "updatedon": "2026-03-12T11:33:06.791Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/dydrogesterone-10-mg/2258", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "DABROSTON 10", "category": "GYANECOLOGYRANGE", "tags": [ "Dydrogesterone 10 mg", "Menstrual Disorders.", "Prevention of Miscarriage.", "Premenstrual Syndrome (PMS).", "endometrial tissue proliferation outside the uterus.", "Endometriosis Management.", "hormonal treatments.", "dydrogesterone 10 mg.", "dydrogesterone 10 mg tablet uses.", "dydrogesterone 10 mg tablet uses in hindi", "dydrogesterone 10 mg tablet uses in pregnancy.", "tablet dydrogesterone 10 mg.", "dydrogesterone 10 mg in pregnancy.", "dydrogesterone 10 mg tablet price." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d999cc236afd258ed10348", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nintedanib 100 mg", "description": "NINTEDONE 100 \nNintedanib 100 mg is a cutting-edge oral medication designed to combat progressive lung conditions and certain cancers, offering hope to patients facing debilitating fibrotic diseases. As a small-molecule tyrosine kinase inhibitor, it targets key pathways involved in abnormal cell growth and tissue scarring, making it a vital therapy for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrosing interstitial lung diseases (PF-ILD). Manufactured to high standards, this formulation delivers precise dosing in a convenient capsule form, ensuring consistent absorption and efficacy for long-term management.​\n\nUses of Nintedanib 100 mg\nNintedanib 100 mg stands out for its approved indications in slowing the decline of lung function in adults with IPF, a chronic and fatal lung disease characterized by progressive scarring of lung tissue. It is also indicated for SSc-ILD, where it helps manage lung fibrosis associated with systemic sclerosis, and PF-ILD, covering other chronic fibrosing lung conditions with a progressive phenotype. Beyond pulmonary fibrosis, Nintedanib has shown utility in oncology, particularly when combined with docetaxel for second-line treatment of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology, inhibiting tumor angiogenesis and growth.​\n\nThis medication addresses the underlying fibrotic processes by restricting fibroblast proliferation and migration, which are central to lung tissue damage. In clinical practice, physicians prescribe Nintedanib 100 mg for patients with confirmed diagnoses via high-resolution CT scans or lung biopsies, often after other treatments fail. Its versatility extends to off-label considerations in other cancers like pancreatic or colorectal, though primary use remains in respiratory fibrosis and lung cancer, providing a targeted approach where traditional therapies fall short.​\n\nKey Benefits of Nintedanib 100 mg\nOne of the primary benefits of Nintedanib 100 mg is its proven ability to reduce the rate of forced vital capacity (FVC) decline, a key measure of lung function, by up to 50% in IPF patients compared to placebo in landmark trials. This translates to slower disease progression, fewer acute exacerbations, and improved quality of life, allowing patients to maintain daily activities longer. The oral administration enhances patient compliance, avoiding the need for infusions or hospital visits.​\n\nSlows Fibrosis Progression: By inhibiting multiple tyrosine kinases, it curbs excessive scar tissue formation in the lungs, preserving respiratory capacity over time.​\n\nAnti-Angiogenic Effects: In cancer settings, it blocks vascular endothelial growth factor receptors (VEGFR), reducing tumor blood supply and metastasis risk.​\n\nBroad-Spectrum Kinase Inhibition: Targets fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and others, addressing multifaceted disease pathways.​\n\nManageable Long-Term Use: Clinical data supports sustained benefits with dose adjustments, minimizing hospitalizations for respiratory failure.​\n\nImproved Survival Metrics: In combination therapies for NSCLC, it extends progression-free survival, offering valuable time for patients.​\n\nThese advantages make Nintedanib 100 mg a cornerstone in modern pulmonology and oncology, backed by phase III trials demonstrating statistically significant outcomes in diverse patient populations.​\n\nSide Effects of Nintedanib 100 mg\nWhile effective, Nintedanib 100 mg can cause gastrointestinal side effects as the most common issue, affecting over 60% of users primarily due to its impact on kinase signaling in the gut. Diarrhea often starts within the first two weeks and is typically manageable with dose reduction or antidiarrheal agents like loperamide. Other frequent effects include nausea, vomiting, and decreased appetite, which may lead to weight loss if not addressed.​\n\nMore serious side effects warrant close monitoring:\n\nLiver Enzyme Elevations: Hepatotoxicity occurs in about 10-15% of patients, necessitating monthly liver function tests, especially in those with pre-existing liver conditions.​\n\nCardiovascular Risks: Potential for arterial thromboembolism or hypertension; baseline cardiac evaluation is recommended.​\n\nBleeding Events: Due to VEGF inhibition, minor bleeding like epistaxis is common, but gastrointestinal hemorrhage requires immediate attention.​\n\nRare but Severe: Interstitial lung disease progression (paradoxical worsening), perforations, or severe infections in immunocompromised patients.​\n\nPatients should report persistent diarrhea, abdominal pain, jaundice, or unusual fatigue promptly. Contraindications include pregnancy (category D), active bleeding, or hypersensitivity, with strong recommendations against use in moderate to severe hepatic impairment.​\n\nDosage and Administration Insights\nTypically initiated at 150 mg twice daily for IPF and ILD, Nintedanib 100 mg allows for flexible dosing—starting lower at 100 mg BID if tolerated poorly, with food to reduce GI upset. For NSCLC, it's 200 mg BID with docetaxel cycles. Regular monitoring every 2-3 months adjusts for tolerance, emphasizing adherence to slow disease modification.​\n\nConclusion\nNintedanib 100 mg represents a breakthrough in managing progressive fibrotic lung diseases and select cancers, delivering targeted inhibition of fibrotic and angiogenic pathways for tangible clinical benefits. Its ability to slow FVC decline, enhance patient quality of life, and integrate into combination regimens underscores its value, despite manageable side effects like diarrhea that respond well to supportive care. For those battling IPF, SSc-ILD, or NSCLC, Nintedanib 100 mg offers a proactive defense against relentless progression, empowering longer, more active lives under specialist guidance.​", "price": 795.0, "discountamount": 296.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one capsule", "weight loss", "scar tissue", "key players", "Key Benefits", "lung function", "initial stages", "abdominal pain", "fibrous tissue", "key ingredient", "Bleeding Events", "fibrotic tissue", "daily activities", "tyrosine kinases", "fibrotic process", "Nintedanib 100 mg", "multiple pathways", "active ingredient", "sudden worsenings", "crucial medication", "recommended dosage", "Decreased Appetite", "signaling pathways", "multiple receptors", "overall well-being", "disease progression", "acute exacerbations", "healthcare provider", "Common side effects", "elevated liver enzymes", "Gastrointestinal Issues", "other fibrotic diseases", "Liver Enzyme Elevations", "tyrosine kinase inhibitor", "progressive lung conditions", "other fibrotic lung diseases", "idiopathic pulmonary fibrosis", "potent pharmaceutical formulation", "fibroblast growth factor receptor", "platelet-derived growth factor receptor", "vascular endothelial growth factor receptor" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1971, "imageuri": "https://productimages.withfloats.com/actual/66d999d4f2036c2969cdeca8.png", "tileimageuri": "https://productimages.withfloats.com/tile/66d999d4f2036c2969cdeca8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-05T11:45:16.665Z", "updatedon": "2026-03-14T06:46:45.85Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//nintedanib-100-mg/1971", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NINTEDONE 100 ", "category": "NEPHROLOGYRANGE", "tags": [ "lung conditions and certain cancers", "Nintedanib 100 mg", "pulmonary fibrosis (IPF)", "fibrosis and lung cancer", "nintedanib 100 mg", "nintedanib capsules 100 mg", "nintedanib 100 mg capsules", "nintedanib 100 mg medicine", "nintedanib 100 mg tablet uses", "what is nintedanib 100 mg used for", "how nintedanib 100 mg works", "nintedanib 100 mg uses and benefits", "nintedanib 100 mg for lung disease", "nintedanib 100 mg for pulmonary fibrosis", "nintedanib 100 mg for idiopathic pulmonary fibrosis", "nintedanib 100 mg for interstitial lung disease", "nintedanib capsules for chronic lung disease", "nintedanib 100 mg price in india", "nintedanib 100 mg capsules price", "buy nintedanib 100 mg online", "nintedanib 100 mg supplier india", "nintedanib 100 mg manufacturer", "when should nintedanib 100 mg be taken", "who should take nintedanib 100 mg", "can nintedanib slow lung fibrosis", "how long to take nintedanib 100 mg", "does nintedanib cure pulmonary fibrosis" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666be6b8aa93342004eef58f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ROPINPRIME 2 ", "description": "ROPINPRIME 2 \nRopinirole (2 mg)\nIntroduction:\nRopinprime 2 is a medication containing Ropinirole, a potent dopamine agonist used primarily for treating Parkinson's disease and restless legs syndrome (RLS). With a dosage strength of 2mg, Ropinprime 2 is designed to effectively alleviate symptoms by mimicking dopamine's action in the brain, thus improving motor function and enhancing the quality of life for patients.\nKey Features and Benefits:\nDopamine Agonist:\nRopinprime 2 acts as a dopamine agonist, stimulating dopamine receptors in the brain. This action helps reduce motor symptoms associated with Parkinson's disease, such as tremors, stiffness, and bradykinesia (slowed movement).\nImproved Motor Function:\n\nBy enhancing dopaminergic activity, Ropinprime 2 aids in improving overall motor function, allowing patients to perform daily activities with greater ease and independence.\nRestless Legs Syndrome Relief:\n\nRopinprime 2 is also effective in managing the symptoms of restless legs syndrome (RLS), a condition characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. Ropinirole helps reduce these symptoms, improving sleep quality and overall comfort.\nFlexible Dosing:\n\nThe 2 mg dosage strength allows for flexible dosing regimens, enabling healthcare providers to tailor treatment plans based on individual patient needs, symptom severity, and response to therapy.\nDosage and Administration:\n\nInitial Dosage for Parkinson's Disease:\n\nThe recommended starting dose of Ropinprime 2 for Parkinson's disease is typically 0.25mg taken three times daily. The dose can be gradually increased based on clinical response and tolerability. Maintenance doses usually range from 1mg to 8mg per day, divided into multiple doses.\nInitial Dosage for Restless Legs Syndrome:\n\nFor RLS, the initial dose is usually 0.25mg taken once daily, 1 to 3 hours before bedtime. The dose may be increased to 0.5mg and then to 1 mg, depending on patient response and symptom control.\nAdministration Instructions:\n\nSwallow Ropinprime 2 tablets whole with water, with or without food. Taking the medication with food may help reduce the likelihood of nausea.\nContinued Monitoring:\n\nRegular monitoring of symptoms, motor function, and potential side effects is essential during Ropinprime 2 therapy to ensure therapeutic efficacy and patient safety.\n\n\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \n", "price": 126.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "RLS", "1mg", "8mg", "life", "aids", "food", "brain", "Order", "EMAIL", "0.5mg", "water", "0.25mg", "action", "nausea", "bedtime", "disease", "tremors", "patients", "Benefits", "condition", "Parkinson", "stiffness", "Ropinirole", "likelihood", "medication", "information", "Introduction", "bradykinesia", "independence", "tolerability", "initial dose", "sterisonline", "sterispharma", "greater ease", "Key Features", "CALL/WHATSAPP", "sleep quality", "starting dose", "motor symptoms", "patient safety", "multiple doses", "Initial Dosage", "overall comfort", "treatment plans", "slowed movement", "symptom control", "patient response", "symptom severity", "daily activities", "clinical response", "Maintenance doses", "Regular monitoring", "dopamine receptors", "uncontrollable urge", "2mg dosage strength", "Ropinprime 2 therapy", "healthcare providers", "therapeutic efficacy", "Continued Monitoring", "dopaminergic activity", "overall motor function", "potential side effects", "potent dopamine agonist", "Improved Motor Function", "uncomfortable sensations", "flexible dosing regimens", "individual patient needs", "Administration Instructions", "Swallow Ropinprime 2 tablets", "Restless Legs Syndrome Relief" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1895, "imageuri": "https://productimages.withfloats.com/actual/667d15dbce74849f89cdd68a.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d15dbce74849f89cdd68a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T06:44:08.261Z", "updatedon": "2026-03-13T07:53:13.869Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//ropinprime-2-/1895", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ROPINPRIME 2 ", "category": "NEUROLOGY RANGE", "tags": [ "Ropinirole (2mg)", "ROPINPRIME 2", "ropinirole side effects", "ropinirole side effects: weight gain", "ropinirole side effects in elderly" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666be4714cb45413344ec323", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ROPINPRIME 0.5 ", "description": "ROPINPRIME 0.5 \nRopinirole (0.5mg)\nIntroduction:\n\nRopinprime 0.5 contains Ropinirole, a dopamine agonist used primarily for treating Parkinson's disease and restless legs syndrome (RLS). With a dosage strength of 0.5mg, Ropinprime 0.5 aims to alleviate symptoms by mimicking the action of dopamine in the brain, thus improving motor function and enhancing quality of life for patients.\nKey Features and Benefits:\n\nDopamine Agonist:\n\nRopinprime 0.5 acts as a dopamine agonist, directly stimulating dopamine receptors in the brain. This action helps reduce the motor symptoms associated with Parkinson's disease, such as tremors, stiffness, and bradykinesia (slowed movement).\nImproved Motor Function:\n\nBy enhancing dopaminergic activity, Ropinprime 0.5 aids in improving overall motor function, allowing patients to perform daily activities with greater ease and independence.\nRestless Legs Syndrome Relief:\n\nRopinprime 0.5 is also effective in managing the symptoms of restless legs syndrome (RLS), a condition characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. Ropinirole helps reduce these symptoms, improving sleep quality and overall comfort.\nFlexible Dosing:\n\nThe 0.5mg dosage strength allows for flexible dosing regimens, enabling healthcare providers to tailor treatment plans based on individual patient needs, symptom severity, and response to therapy.\nDosage and Administration:\n\nInitial Dosage:\nThe recommended starting dose of Ropinprime 0.5 for Parkinson's disease is typically 0.25mg taken three times daily. The dose can be gradually increased based on clinical response and tolerability.\nRestless Legs Syndrome:\nFor RLS, the initial dose is usually 0.25mg taken once daily, 1 to 3 hours before bedtime. Dosage may be adjusted according to patient response and symptom control.\nAdministration Instructions:\nSwallow Ropinprime 0.5 tablets whole with water, with or without food. Taking the medication with food may help reduce the likelihood of nausea.\nContinued Monitoring:\nRegular monitoring of symptoms, motor function, and potential side effects is essential during Ropinprime 0.5 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \nhttps://www.sterisonline.com/product/ropinprime-0-5-133627", "price": 56.0, "discountamount": 16.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "RLS", "aids", "life", "food", "Order", "water", "brain", "EMAIL", "0.25mg", "nausea", "action", "bedtime", "disease", "tremors", "patients", "Benefits", "stiffness", "condition", "Parkinson", "Ropinirole", "likelihood", "medication", "information", "Introduction", "initial dose", "independence", "greater ease", "tolerability", "Key Features", "sterispharma", "bradykinesia", "sterisonline", "CALL/WHATSAPP", "sleep quality", "starting dose", "patient safety", "motor symptoms", "Initial Dosage", "overall comfort", "treatment plans", "slowed movement", "symptom control", "dopamine agonist", "patient response", "daily activities", "symptom severity", "clinical response", "Regular monitoring", "dopamine receptors", "uncontrollable urge", "Continued Monitoring", "healthcare providers", "therapeutic efficacy", "0.5mg dosage strength", "dopaminergic activity", "Ropinprime 0.5 therapy", "overall motor function", "potential side effects", "Improved Motor Function", "individual patient needs", "uncomfortable sensations", "flexible dosing regimens", "Administration Instructions", "Restless Legs Syndrome Relief", "Swallow Ropinprime 0.5 tablets" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1893, "imageuri": "https://productimages.withfloats.com/actual/666be475844f2600246a0b63.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/666be475844f2600246a0b63.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T06:34:25.708Z", "updatedon": "2026-03-12T11:33:24.735Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//ropinprime-0-5-/1893", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ROPINPRIME 0.5 ", "category": "NEUROLOGY RANGE", "tags": [ "ropinprime 0.5 mg tablet 10", "ropinprime 0.5 mg tablet uses", "ropin 0.5 injection", "ropinirole warnings", "ropinirole side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666ae69aaebebd0900165264", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RASAGAIL 1", "description": "RASAGAIL 1\nRasagail 1.0 \nIntroduction:\n\nRasagail 1.0 embodies the therapeutic efficacy of Rasagiline, a potent monoamine oxidase-B (MAO-B) inhibitor renowned for its role in managing Parkinson's disease. With a dosage strength of 1.0mg, Rasagail 1.0 offers a targeted approach to alleviate symptoms, enhance motor function, and potentially slow disease progression in Parkinson's patients.\nKey Features and Benefits:\n\nMAO-B Inhibition:\n\nRasagail 1.0 exerts its primary action by selectively inhibiting MAO-B enzymes, leading to increased dopamine levels within the brain's striatum. This mechanism aids in alleviating motor symptoms and improving overall motor function.\nNeuroprotection:\n\nBeyond symptom relief, Rasagail 1.0 demonstrates neuroprotective properties by reducing oxidative stress, preserving neuronal integrity, and potentially exerting disease-modifying effects in Parkinson's disease.\nImproved Motor Function:\n\nBy enhancing dopaminergic neurotransmission, Rasagail 1.0 contributes to smoother motor coordination, reduced rigidity, tremors, and bradykinesia, fostering greater mobility and functional independence.\nFlexible Dosing:\n\nRasagail 1.0 allows for flexible dosing regimens, enabling healthcare providers to tailor treatment plans based on individual patient needs, disease severity, and response to therapy.\nDosage and Administration:\n\nInitial Dosage:\nThe recommended starting dose of Rasagail 1.0 is 1.0mg once daily, administered orally with or without food. Dosage adjustments may be considered based on individual patient response and tolerability.\nTitration and Maintenance:\nTitration of Rasagail 1.0 may occur under medical supervision to achieve optimal therapeutic benefits while minimizing adverse effects. Maintenance doses are typically adjusted as needed to sustain symptom control.\nContinued Monitoring:\nOngoing clinical monitoring of Parkinson's disease symptoms, motor function, and potential side effects is essential during Rasagail 1.0 therapy to ensure treatment efficacy and patient safety.For further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \nhttps://www.sterisonline.com/product/rasagail-1-0-133623\n", "price": 135.0, "discountamount": 40.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "role", "food", "brain", "1.0mg", "Order", "EMAIL", "tremors", "patients", "rigidity", "striatum", "Titration", "Parkinson", "mechanism", "Rasagiline", "information", "Introduction", "Key Features", "sterisonline", "sterispharma", "tolerability", "bradykinesia", "starting dose", "CALL/WHATSAPP", "MAO-B enzymes", "Initial Dosage", "Administration", "patient safety", "symptom relief", "motor symptoms", "primary action", "treatment plans", "adverse effects", "symptom control", "dosage strength", "Neuroprotection", "dopamine levels", "MAO-B Inhibition", "disease symptoms", "disease severity", "greater mobility", "oxidative stress", "MAO-B) inhibitor", "Maintenance doses", "targeted approach", "treatment efficacy", "neuronal integrity", "Dosage adjustments", "medical supervision", "disease progression", "healthcare providers", "Continued Monitoring", "therapeutic efficacy", "Rasagail 1.0 therapy", "potential side effects", "overall motor function", "functional independence", "Improved Motor Function", "individual patient needs", "flexible dosing regimens", "disease-modifying effects", "potent monoamine oxidase-B", "neuroprotective properties", "Ongoing clinical monitoring", "smoother motor coordination", "individual patient response", "optimal therapeutic benefits", "dopaminergic neurotransmission" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1888, "imageuri": "https://productimages.withfloats.com/actual/666ae69dc9162f54a1593ccc.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/666ae69dc9162f54a1593ccc.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-13T12:31:22.172Z", "updatedon": "2026-03-12T11:27:42.379Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//rasagail-1/1888", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RASAGAIL 1", "category": "NEUROLOGY RANGE", "tags": [ "RASAGAIL 1", "rasagiline 1 mg price", "rasagiline 1 mg uses", "rasagiline benefits", "rasagiline side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661a57d8da3a81d5c6a17dd", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Mycophenolate mofetil 500mg", "description": "MYCOPLASM M 500\nMycophenolate mofetil (500mg)\nMycoplasm M 500 is a medication containing Mycophenolate Mofetil in a 500mg dose. Mycophenolate Mofetil is an immunosuppressive drug used to prevent rejection in organ transplantation, particularly kidney, heart, and liver transplants. It works by inhibiting the proliferation of T and B lymphocytes, which are involved in the immune response that leads to rejection.\n\nThis medication is typically prescribed in combination with other immunosuppressants as part of a comprehensive transplant treatment regimen. It is important to take Mycoplasm M 500 exactly as prescribed by your healthcare provider to ensure optimal therapeutic outcomes and to minimize the risk of rejection or other complications.\n\nCommon side effects of Mycophenolate Mofetil may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. It can also increase the risk of infections due to its immunosuppressive effects. Patients should be monitored regularly by their healthcare provider while taking this medication to assess for any potential adverse effects and to adjust the dosage as needed.\n\nMycoplasm M 500 should not be used in pregnant women or those planning to become pregnant without consulting a healthcare professional, as it can cause harm to the developing fetus. Additionally, it may interact with other medications, so it is important to inform your doctor about all the medications you are currently taking before starting Mycoplasm M 500 therapy.For further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \n\n\n\n\nMycophenolate mofetil 500 mg stands as a cornerstone in modern immunosuppressive therapy, primarily designed to prevent organ transplant rejection in kidney, heart, and liver recipients. As a prodrug, it rapidly converts to its active form, mycophenolic acid (MPA), which selectively targets the proliferation of T and B lymphocytes—key players in immune responses that can attack transplanted organs. This medication, available in convenient 500 mg tablets, offers reliable protection against acute rejection episodes, making it an essential component in post-transplant regimens worldwide.​\n\nProduct Uses\nMycophenolate mofetil 500 mg finds its primary application in solid organ transplantation, where it helps maintain long-term graft survival. For kidney transplant patients, it is typically administered alongside corticosteroids and calcineurin inhibitors like cyclosporine or tacrolimus to suppress the immune system's overreaction to the new organ. In heart and liver transplants, it plays a similar role, reducing the incidence of rejection by inhibiting antibody production and cell-mediated immunity.​\n\nBeyond transplants, healthcare providers increasingly use mycophenolate mofetil 500 mg for various autoimmune conditions. It effectively manages lupus nephritis by curbing inflammation in the kidneys, showing superior efficacy over traditional therapies in preserving renal function. Rheumatoid arthritis patients benefit from its ability to dampen joint inflammation, while those with dermatomyositis or scleroderma experience reduced skin and muscle involvement. Off-label, it treats inflammatory bowel diseases like Crohn's disease and even certain skin disorders such as pemphigus vulgaris, where immune-mediated blistering threatens quality of life.​\n\nKey Benefits\nThe therapeutic advantages of mycophenolate mofetil 500 mg extend far beyond basic immunosuppression, offering patients enhanced outcomes and improved daily living.\n\nSuperior Graft Protection: Clinical data highlight reduced acute rejection rates by up to 50% when combined with standard regimens, leading to better long-term organ function and survival.​\n\nSelective Lymphocyte Targeting: By depleting guanosine nucleotides in T and B cells via inosine monophosphate dehydrogenase (IMPDH) inhibition, it spares other cell types, minimizing broad toxicity seen with older immunosuppressants.​\n\nAnti-Inflammatory Effects: MPA inhibits adhesion molecule glycosylation, preventing lymphocyte recruitment to inflamed sites, which alleviates symptoms in autoimmune flares.​\n\nOral Convenience: The 500 mg formulation allows flexible dosing—typically 1 gram twice daily—without the need for injections, improving patient adherence.​\n\nVersatility Across Conditions: Proven efficacy in lupus, vasculitis, and myositis expands its utility, often allowing steroid dose reduction and fewer relapses.​\n\nCardiovascular and Anticancer Potential: Emerging evidence suggests it delays graft atherosclerosis by reducing lipid oxidation and may hinder tumor progression in certain malignancies due to its impact on nucleotide synthesis.​\n\nThese benefits translate to fewer hospital readmissions, better quality of life, and cost savings in long-term care for transplant and autoimmune patients.​\n\nSide Effects\nWhile mycophenolate mofetil 500 mg provides robust immunosuppression, it carries risks typical of this drug class, necessitating vigilant monitoring.\n\nCommon side effects affect the gastrointestinal tract most prominently, with nausea, vomiting, diarrhea, and abdominal pain occurring in over 30% of users. These often improve with dose adjustments or enteric-coated alternatives, but hydration and antiemetics help manage them effectively.​\n\nHematologic issues like leukopenia, anemia, and thrombocytopenia arise due to bone marrow suppression, requiring regular complete blood counts—weekly initially, then monthly. Infections pose a significant threat, as suppressed immunity increases susceptibility to viral (e.g., CMV), bacterial, and fungal pathogens; prophylactic antivirals are standard.​\n\nLess frequent but notable effects include hypertension, tremor, insomnia, and elevated liver enzymes. Women face heightened risks of congenital malformations if used during pregnancy, mandating effective contraception and pregnancy testing. Rare severe reactions encompass progressive multifocal leukoencephalopathy (PML) from JC virus reactivation and hypersensitivity syndromes.​\n\nDosage and Administration Notes\nStandard dosing for renal transplants involves 1 gram (two 500 mg tablets) twice daily, starting within 72 hours post-surgery, with adjustments for renal impairment. Hepatic transplant patients may require higher initial doses due to metabolism differences. Always take on an empty stomach with water to optimize absorption, avoiding antacids that bind MPA.​\n\nPrecautions and Interactions\nPatients must avoid live vaccines, report fevers promptly, and undergo TB screening pre-treatment. Drug interactions with azathioprine, cholestyramine, or rifampin can alter levels, so pharmacists review regimens closely. Regular monitoring of MPA blood levels ensures therapeutic efficacy without toxicity.​\n\nConclusion\nMycophenolate mofetil 500 mg emerges as a transformative immunosuppressive agent, safeguarding transplanted organs and taming autoimmune storms with its precise mechanism of lymphocyte suppression and anti-inflammatory prowess. By delivering key benefits like reduced rejection, versatile applications, and manageable administration, it empowers patients to reclaim normalcy post-transplant or amid chronic illness. Despite potential side effects, proactive monitoring and personalized dosing mitigate risks, underscoring its value in contemporary medicine. For those navigating transplant recovery or autoimmune challenges, this medication offers hope and stability, backed by decades of clinical validation.\n\n", "price": 775.0, "discountamount": 256.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "part", "Call", "harm", "risk", "Email", "heart", "ORDER", "nausea", "kidney", "dosage", "doctor", "vomiting", "WhatsApp", "Patients", "diarrhea", "rejection", "infections", "500mg dose", "combination", "information", "sterisonline", "proliferation", "B lymphocytes", "abdominal pain", "pregnant women", "immune response", "developing fetus", "other medications", "liver transplants", "other complications", "healthcare provider", "Common side effects", "organ transplantation", "Mycophenolate mofetil", "immunosuppressive drug", "Mycoplasm M 500 therapy", "healthcare professional", "other immunosuppressants", "immunosuppressive effects", "potential adverse effects", "optimal therapeutic outcomes", "gastrointestinal disturbances", "comprehensive transplant treatment regimen" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1472, "imageuri": "https://productimages.withfloats.com/actual/6661a57fdd39d2ccddbc3bb9.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661a57fdd39d2ccddbc3bb9.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:03:09.216Z", "updatedon": "2026-03-12T08:00:39.14Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//mycophenolate-mofetil-500mg/1472", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MYCOPLASM M 500", "category": "NEPHROLOGYRANGE", "tags": [ "MYCOPLASM M 500", "Mycophenolate mofetil (500mg)", "Mycophenolate mofetil 500 mg tablet", "Mycophenolate mofetil 500 mg price", "Mycophenolate mofetil 500 mg dosage", "Mycophenolate mofetil uses", "Mycophenolate mofetil side effects", "mycophenolate mofetil 500mg tablet uses", "mycophenolate mofetil 500mg dosage for kidney transplant", "mycophenolate mofetil 500mg for autoimmune disease" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6a952bdada41ea9aeeec5e4a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide injection 8 mg", "description": "The semaglutide injection, 8 mg, contains a total of 8 mg of semaglutide, a long-acting GLP-1 receptor agonist. It is used under medical supervision as part of treatment for appropriate adults with type 2 diabetes mellitus and, depending on the specific approved product and indication, for cardiovascular risk reduction and chronic weight management.\n1. Product Overview & Specifications\nAn 8 mg/3 mL semaglutide pen contains 8 mg of the active medicine in a 3 mL delivery system. When specifically designed to provide 2 mg per weekly dose, the total quantity can provide four 2 mg doses.\nActive Ingredient: Semaglutide\nTotal Strength: 8 mg\nExample Presentation: 8 mg/3 mL multi-dose pen\nDrug Class: GLP-1 receptor agonist\nRoute: Subcutaneous injection\nCommon Injection Areas: Abdomen, thigh, or upper arm\nAdministration: Once weekly, according to the prescribed schedule\nMechanism of Action\nSemaglutide mimics the activity of the naturally occurring hormone GLP-1 (glucagon-like peptide-1). It acts on GLP-1 receptors involved in blood-glucose regulation, digestion, and appetite.\nImproves glucose-dependent insulin release: Semaglutide encourages the pancreas to release insulin when blood glucose levels are elevated.\nReduces glucagon secretion: It lowers inappropriate glucagon release, helping reduce the amount of glucose produced by the liver.\nSlows gastric emptying: Semaglutide can delay the movement of food from the stomach, contributing to prolonged fullness.\nReduces appetite: Its effects on appetite-regulating pathways in the brain can decrease hunger and food intake.\n2. Primary Indications & Uses\nSemaglutide may be prescribed for several clinically established purposes depending on the specific formulation, approved labeling, and patient's medical condition.\nType 2 Diabetes Management\nSemaglutide can be used alongside appropriate diet and physical activity to improve blood-glucose control in adults with type 2 diabetes.\nCardiovascular Risk Reduction\nIn eligible adults with type 2 diabetes and established cardiovascular disease, certain semaglutide products have demonstrated a reduction in the risk of major cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke.\nKidney Disease\nCertain semaglutide formulations and indications have demonstrated kidney-related benefits in specific populations. The appropriate product and indication should be determined by a healthcare professional.\nChronic Weight Management\nSemaglutide is also used for long-term weight management in eligible adults with obesity or overweight accompanied by weight-related health conditions, depending on the approved formulation and local prescribing guidance.\n3. Key Benefits of Semaglutide 8 mg Therapy\nClinical Area\nPotential Therapeutic Role\nBlood-Glucose Control\nHelps lower elevated blood glucose and improve glycemic control in appropriate patients.\nWeight Management\nReduces appetite and food intake, supporting sustained weight reduction when prescribed for this purpose.\nCardiovascular Health\nCertain approved semaglutide indications can reduce major cardiovascular event risk in eligible patients.\nMetabolic Support\nInfluences glucose regulation, appetite, insulin secretion, and glucagon activity.\nWeekly Administration\nA once-weekly injection can provide a convenient treatment schedule when prescribed.\n\n4. Side Effects & Safety Warnings\nCommon Adverse Reactions\nDigestive symptoms are among the most frequently reported adverse effects, particularly when treatment is initiated or the dose is increased.\nPossible side effects include:\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort\nBloating\nBelching\nIndigestion or heartburn\nReduced appetite\nThese effects may improve as the body becomes accustomed to treatment.\nFrequently Asked Questions\n1. How much weight can you lose with semaglutide?\nWeight reduction varies significantly between individuals and depends on the prescribed formulation, dose, treatment duration, diet, physical activity, and adherence. Clinical trials of approved weight-management regimens have demonstrated substantial average percentage weight loss over extended treatment periods.\n2. How much is 8 units of semaglutide in mL?\nOn a U-100 insulin syringe, 100 units corresponds to 1 mL, so 8 units corresponds to 0.08 mL. However, this conversion only describes syringe volume. It does not determine the amount of semaglutide in mg because the medication concentration varies between products. Always verify the exact concentration before measuring any dose.\n3. Is semaglutide injection safe for weight loss?\nSemaglutide can be an effective treatment for weight management when an approved formulation is prescribed to an eligible patient and used under appropriate medical supervision. It has important contraindications and warnings, including risks involving the gastrointestinal system, gallbladder, pancreas, kidneys, and thyroid C-cell tumors.\n4. How many mg of semaglutide are used for weight loss?\nThe appropriate dose depends on the specific semaglutide product. Weight-management treatment commonly begins with a lower dose and is gradually increased to a maintenance dose to improve tolerability. The maintenance dose should be determined according to the product's approved prescribing information and the healthcare professional's instructions.\n5. How much weight can I lose in 2 months with semaglutide?\nThere is no guaranteed amount of weight loss during the first two months. Individual results vary because treatment generally begins at a lower dose and is increased gradually. Diet, physical activity, starting weight, medical conditions, and adherence also affect the result.\n6. What happens when you stop semaglutide?\nAfter discontinuation, semaglutide gradually leaves the body. Appetite and food intake may increase as its effects decrease, and some people regain weight. Maintaining healthy eating and physical activity habits may help support weight management after treatment, but discontinuation should be discussed with a healthcare professional.\n7. How long does an 8 mg/3 mL semaglutide pen last?\nIf a specific 8 mg/3 mL pen is designed to deliver 2 mg per weekly dose, it contains four 2 mg doses and therefore provides approximately four weeks of treatment. The actual duration depends on the specific device and prescribed dosing instructions.\n8. What is semaglutide injection 8 mg used for?\nSemaglutide is used for approved indications such as improving blood-glucose control in type 2 diabetes and, depending on the formulation, supporting chronic weight management and reducing cardiovascular risk in eligible patients.\n9. What foods should be avoided while taking semaglutide?\nLarge, high-fat, greasy, or fried meals may worsen gastrointestinal symptoms such as nausea, bloating, and reflux. Smaller meals and balanced food choices may be easier to tolerate. Alcohol intake should also be discussed with a healthcare professional.\n10. Can you eat bananas while taking semaglutide?\nYes, bananas can generally be included in a balanced diet while using semaglutide. Portion size should be considered as part of an individual's overall calorie and carbohydrate intake, particularly for people managing diabetes.\n11. What is the best time of day to inject semaglutide?\nSemaglutide injections can generally be administered at any time of day, with or without meals, depending on the specific product instructions. The injection should be taken on the same day each week as prescribed.\n12. Will I lose weight during the first week of semaglutide?\nSome people may notice an early change in appetite or body weight, while others may not see a significant difference initially. Early treatment doses are generally introduced gradually to help the body adjust rather than to produce immediate maximum weight loss.\n13. How quickly does semaglutide start lowering blood sugar?\nSemaglutide begins acting after administration, but the degree and timing of blood-glucose improvement vary. Significant treatment effects develop progressively, particularly as the prescribed dose is gradually adjusted.\n14. What should I do if I miss a semaglutide dose?\nThe correct missed-dose procedure depends on the specific semaglutide product. Follow the instructions supplied with your prescribed product. Do not take an extra dose to compensate for a missed injection.\n15. Where is the best place to inject semaglutide?\nSemaglutide is administered subcutaneously. Common injection sites include the abdomen, front of the thigh, or upper arm, according to the product instructions. Rotating injection locations can help reduce repeated irritation at one site.\nConclusion\nSemaglutide injection 8 mg contains semaglutide, a long-acting GLP-1 receptor agonist that influences blood-glucose regulation, glucagon secretion, gastric emptying, and appetite. Depending on the specific formulation and approved indication, semaglutide may be used for type 2 diabetes management, chronic weight management, and cardiovascular risk reduction in eligible patients.\nAn 8 mg/3 mL presentation designed for 2 mg weekly dosing can provide four weekly doses. However, semaglutide concentrations, pen designs, approved doses, and indications can differ between products. Treatment should therefore follow the exact product instructions and a healthcare professional's prescription.", "price": 7800.0, "discountamount": 2340.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2498, "imageuri": "https://productimages.withfloats.com/actual/6a952bdd8359c1b7edbc7468.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a952bdd8359c1b7edbc7468.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-31T07:23:06.814Z", "updatedon": "2026-08-31T07:23:06.814Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//semaglutide-injection-8-mg/2498", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 8MG", "category": "DIABETIC RANGE", "tags": [ "Semaglutide injection 8 mg", "semaglutide injection 8 mg", "semaglutide 8 mg injection uses", "semaglutide 8 mg injection benefits", "semaglutide 8 mg injection dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a8c3838c90065ecdc86c757", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide Injection 4mg", "description": "SAMIGLUTIDE 4 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation contains 4 mg of semaglutide in 3 mL of solution, corresponding to approximately 1.34 mg/mL.\n\nSemaglutide is a GLP-1 receptor agonist that acts on physiological pathways involved in blood-glucose control, appetite, and gastrointestinal function. Its use should be based on the approved indication for the specific product and the advice of a qualified healthcare professional.\n\nProduct Overview\nProduct: SAMIGLUTIDE 4 MG\nActive substance: Semaglutide\nStrength: 4 mg/3 mL\nApproximate concentration: 1.34 mg/mL\nDosage form: Injectable solution\nPresentation: Pre-filled pen\nRoute: Subcutaneous administration, according to the applicable product instructions\n\nThe 4 mg/3 mL concentration is also associated with certain approved semaglutide products. However, this does not mean that their dosing schedules, indications, or administration instructions automatically apply to SAMIGLUTIDE 4 MG. The product-specific labeling should always be followed.\n\nWhat Is Semaglutide?\n\nSemaglutide is a medication belonging to the GLP-1 receptor agonist class. It acts similarly to the naturally occurring hormone glucagon-like peptide-1 (GLP-1).\n\nGLP-1 is involved in several processes related to metabolism. Its activity can influence insulin secretion, glucagon regulation, stomach emptying, and appetite. Depending on the particular semaglutide product and its regulatory authorization, semaglutide may be prescribed for conditions such as type 2 diabetes or chronic weight management in appropriately selected patients.\n\nBecause different semaglutide products can have different approved uses and formulations, treatment decisions should be based on the specific medicine being prescribed.\n\nSAMIGLUTIDE 4 MG Pre-Filled Pen\n\nSAMIGLUTIDE 4 MG is supplied in a pre-filled pen intended to provide a convenient format for subcutaneous administration.\n\nPre-filled devices can eliminate the need to draw medication from a conventional vial. Nevertheless, patients should be properly trained before using an injectable pen and should follow the instructions supplied with the specific product.\n\nThe pen should only be used according to its approved instructions, including the prescribed dose and administration schedule.\n\nStrength and Formulation\n\nEach stated 3 mL presentation contains 4 mg of semaglutide, giving a concentration of approximately 1.34 mg/mL.\n\nThe concentration of a medicine should not be confused with the amount delivered in every injection. The quantity administered depends on the design and dose settings of the particular pen.\n\nFor this reason, patients should not calculate or select their own dose based solely on the concentration printed on the package. The prescribed dose should come from the product's authorized instructions and the treating healthcare professional.\n\nHow Semaglutide Acts\n\nSemaglutide activates GLP-1 receptors, which are involved in the regulation of blood glucose and appetite.\n\nAmong its physiological effects, GLP-1 receptor activation can:\n\nSupport glucose-dependent insulin secretion.\nReduce inappropriate glucagon secretion when blood glucose is elevated.\nAffect gastrointestinal activity, including gastric emptying.\nInfluence appetite and food intake.\n\nThe overall response to treatment can vary between individuals and depends on factors such as the medical indication, prescribed dose, treatment duration, and other medicines being used.\n\nPotential Therapeutic Benefits\n\nWhen prescribed for an appropriate, authorized indication, semaglutide may form part of a broader treatment program.\n\nFor eligible individuals with type 2 diabetes, certain approved semaglutide medicines are used to improve glycemic control. Other approved semaglutide formulations have indications involving chronic weight management for qualifying patients.\n\nMedication should be considered alongside the broader treatment strategy recommended by a healthcare professional, which may include nutritional management, physical activity, glucose monitoring, and other appropriate interventions.\n\nPossible Side Effects\n\nLike other prescription medicines, semaglutide can cause unwanted effects.\n\nFrequently reported gastrointestinal reactions associated with semaglutide products include:\n\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort or pain\n\nNot every patient experiences these effects, and their severity can vary.\n\nSemaglutide products also have important safety considerations. Depending on the specific approved product, labeling includes warnings concerning conditions such as pancreatitis, gallbladder-related problems, severe gastrointestinal reactions, kidney problems associated with dehydration, and serious hypersensitivity reactions.\n\nPatients should provide their healthcare professional with a complete medical history before treatment begins.\n\nImportant Contraindications and Warnings\n\nCertain semaglutide products carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity to semaglutide or an applicable component is also an important contraindication.\n\nThe exact warnings and contraindications applicable to SAMIGLUTIDE 4 MG should be confirmed against its current authorized product information in the relevant country.\n\nPatients should seek professional medical advice if they develop concerning symptoms during treatment.\n\nCorrect Administration\n\nSAMIGLUTIDE 4 MG should be administered only according to the prescription and instructions applicable to the product.\n\nBefore using a pre-filled pen, patients should receive appropriate instruction regarding:\n\nDose selection\nInjection technique\nInjection sites\nPen operation\nStorage\nDisposal of used needles or injection equipment\n\nThe dose or frequency should never be changed independently.\n\nA pre-filled injection pen should not be shared with another person, even if a new needle is attached. Sharing injectable medication devices can create a risk of transmitting infections and is contrary to appropriate safe-use practices.\n\nStorage\n\nStorage requirements should be determined from the official SAMIGLUTIDE 4 MG packaging and product information supplied with the medicine.\n\nPatients should not rely on storage instructions from a different semaglutide brand because formulations, devices, and stability requirements can differ between products.\n\nUse by Healthcare Professionals\n\nHealthcare professionals should assess whether SAMIGLUTIDE 4 MG is appropriate for an individual patient by considering the relevant diagnosis, treatment objectives, medical history, contraindications, concurrent medicines, and applicable regulatory requirements.\n\nParticular attention should be given to the distinction between different semaglutide products. Although they contain the same active ingredient, products may differ in:\n\nApproved indications\nConcentration\nPen design\nDose increments\nAdministration schedules\nStorage conditions\nRegulatory labeling\n\nThe product-specific prescribing information should therefore be consulted before treatment is initiated or adjusted.\n\nAdvantages of a Pre-Filled Pen\n\nA pre-filled pen can provide a practical method of administering an injectable medicine. Compared with a conventional vial-and-syringe presentation, the device may reduce some preparation steps and can be convenient for patients who have been appropriately trained.\n\nConvenience, however, should not take precedence over product authenticity, regulatory approval, correct dosing, proper storage, and professional medical supervision.\n\nSAMIGLUTIDE 4 MG: Key Points\n\nSAMIGLUTIDE 4 MG is described as a semaglutide injection containing 4 mg in 3 mL, supplied in a pre-filled pen.\n\nThe most important considerations are:\n\nSemaglutide is a GLP-1 receptor agonist.\nThe stated formulation is 4 mg/3 mL (approximately 1.34 mg/mL).\nAdministration is by the subcutaneous route when prescribed for that route.\nThe appropriate dose and frequency must come from the product-specific instructions and prescription.\nDosing information from another semaglutide brand should not automatically be applied.\nPatients should be informed about possible adverse reactions and relevant contraindications.\nThe pen must not be shared between patients.\nStorage and handling should follow the official product information.\nTreatment should be supervised by an appropriately qualified healthcare professional.\nFrequently Asked Questions\nWhat is SAMIGLUTIDE 4 MG?\n\nSAMIGLUTIDE 4 MG is a semaglutide-containing injectable formulation described as 4 mg/3 mL, supplied in a pre-filled pen. Its approved use depends on the regulatory authorization applicable to the product and market.\n\nWhat does 4 mg/3 mL mean?\n\nIt indicates that the stated 3 mL presentation contains a total of 4 mg of semaglutide, equivalent to approximately 1.34 mg of semaglutide per mL.\n\nThis concentration alone should not be used to determine an individual's injection dose.\n\nIs SAMIGLUTIDE 4 MG a prescription medicine?\n\nSemaglutide medicines are prescription products in many jurisdictions. SAMIGLUTIDE 4 MG should be used only in accordance with applicable regulations, authorized product information, and professional medical advice.\n\nHow is SAMIGLUTIDE 4 MG administered?\n\nThe product is described as a subcutaneous injection. However, the exact dose, injection frequency, and pen operation should be determined from the SAMIGLUTIDE 4 MG product information and the patient's prescription.\n\nCan SAMIGLUTIDE 4 MG be taken together with another semaglutide medicine?\n\nPatients should not combine semaglutide-containing medicines or switch between them without medical supervision. Some approved semaglutide labels specifically advise against combining their product with another semaglutide-containing medicine or another GLP-1 receptor agonist.\n\nCan the dose be changed without consulting a doctor?\n\nNo. Patients should not increase, decrease, or otherwise modify the prescribed dose or injection schedule without guidance from their healthcare professional.\n\nConclusion\n\nSAMIGLUTIDE 4 MG – Semaglutide Injection 4 mg/3 mL (approximately 1.34 mg/mL) Pre-Filled Pen is a semaglutide-based injectable formulation designed for subcutaneous use according to its applicable product instructions.\n\nBecause semaglutide products can vary substantially in their approved indications, concentrations, devices, and dosing regimens, information from another semaglutide product should not be assumed to apply to SAMIGLUTIDE 4 MG.\n\nFor appropriate and safe use, patients and healthcare professionals should rely on the current official product information, local regulatory authorization, and individualized medical advice. Any questions concerning suitability, dosing, interactions, contraindications, or adverse effects should be discussed with a qualified healthcare professional.", "price": 6600.0, "discountamount": 1980.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2497, "imageuri": "https://productimages.withfloats.com/actual/6a8c383c0e00e8a5dab0c9d5.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a8c383c0e00e8a5dab0c9d5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-24T12:25:28.659Z", "updatedon": "2026-08-24T12:25:28.659Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//semaglutide-injection-4mg/2497", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 4 MG", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a50b1ae8f6638fa60654b85", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Bromfenac Ophthalmic Solution 0.09% w/v", "description": "Bromfenac ophthalmic solution 0.09% w/v is a prescription non-steroidal anti-inflammatory drug (NSAID) eye drop used primarily to treat pain and inflammation following cataract surgery and to reduce the risk of post-operative cystoid macular edema. Unlike corticosteroid eye drops, bromfenac is not a steroid — it works by inhibiting the cyclooxygenase (COX) enzyme, blocking the production of prostaglandins that drive inflammation, redness, and pain. A key advantage of bromfenac is its once-daily dosing, compared to the multiple daily doses required by many other topical NSAIDs and steroids, which improves ease of use during post-surgical recovery. Common side effects include mild burning or stinging on instillation and temporary blurred vision, while rare but serious risks include corneal complications with prolonged or inappropriate use. It is a Schedule H prescription-only medicine in India.\n\nWhat Is Bromfenac Ophthalmic Solution 0.09% w/v?\nBromfenac ophthalmic solution 0.09% w/v is a topical non-steroidal anti-inflammatory drug (NSAID) formulated for use in the eye. It is most commonly prescribed to manage inflammation and pain following ocular surgery, particularly cataract surgery, and is also used to help reduce the risk of post-operative cystoid macular edema, a swelling of the central retina that can occur after intraocular procedures.\nAs an NSAID, bromfenac differs fundamentally from corticosteroid eye drops. It does not carry the risk of raising intraocular pressure (IOP) that steroids do, making it a valuable option — often used alongside or instead of a steroid — in the post-surgical care protocol, depending on the surgeon's assessment.\nOne of bromfenac's most notable practical advantages is its once-daily dosing schedule, which sets it apart from several other ophthalmic NSAIDs that require two to four applications per day. This simplified regimen can improve patient adherence during the post-operative recovery period.\n\nHow Does Bromfenac Work? (Mechanism of Action)\n\nTissue injury response – Ocular surgery and inflammation trigger the release of arachidonic acid from damaged cell membranes.\nCyclooxygenase (COX) enzyme activity – The COX-1 and COX-2 enzymes convert arachidonic acid into prostaglandins, which are key mediators of inflammation, pain, and vascular permeability.\nCOX inhibition by bromfenac – Bromfenac inhibits both COX-1 and COX-2 enzymes, blocking the prostaglandin synthesis pathway.\nReduced inflammation and pain – With prostaglandin production suppressed, inflammation, redness, and post-surgical discomfort are reduced.\nProtection against macular edema – By limiting prostaglandin-driven vascular permeability, bromfenac also helps lower the risk of fluid accumulation in the macula following surgery.\n\n\nClinical Indications\nIndicationDetailsPost-operative inflammationPrimary use following cataract surgeryPost-operative pain managementReduces surgical site discomfort during recoveryPrevention of post-operative cystoid macular edemaUsed prophylactically around the time of cataract surgeryAdjunct to steroid therapySometimes used alongside corticosteroid drops for comprehensive post-surgical control\n\nDosage & Administration\nParameterRecommendationStandard doseOne drop in the operated eye, once dailyTimingOften started shortly before surgery and continued through the recovery period, as directedDurationTypically a defined post-operative course as prescribed by your ophthalmic surgeonContact lensesAvoid wearing contact lenses during the immediate post-operative period unless advised otherwiseMissed doseApply as soon as remembered; do not double the next doseCombination useMay be prescribed alongside antibiotic and/or steroid eye drops as part of a full post-surgical regimen — space applications as directed\nNote: Always follow your surgeon's specific pre- and post-operative dosing schedule, as timing around the surgery date is clinically important.\n\nKey Benefits\n\nEffectively reduces post-surgical pain and inflammation without the IOP-related risks of steroids\nOnce-daily dosing improves convenience and adherence compared to multi-dose NSAID or steroid regimens\nHelps lower the risk of post-operative cystoid macular edema, a potentially vision-affecting complication\nCan be used alongside steroid and antibiotic eye drops as part of a comprehensive post-surgical protocol\nGenerally does not raise intraocular pressure, unlike corticosteroid alternatives\nSupports a smoother, more comfortable post-operative recovery experience\n\n\nPrecautions\n\nUse strictly as directed by your ophthalmic surgeon, particularly regarding timing before and after surgery\nUse with caution in patients with known bleeding disorders or those taking medications that increase bleeding tendency, as NSAIDs can affect clotting\nRare but serious corneal complications (including delayed healing or, very rarely, corneal thinning) have been reported with prolonged or inappropriate NSAID use — report any unusual eye pain or vision change immediately\nNot recommended for patients with known hypersensitivity to bromfenac or other NSAIDs\nCaution advised in patients with complicated ocular surgeries, pre-existing corneal disease, or dry eye, as these may increase sensitivity to corneal side effects\nAvoid contact lens wear during the treatment period unless specifically advised by your doctor\nInform your doctor of all other eye medications and systemic drugs, especially blood thinners\n\n\nSide Effects\nCommon (Usually Mild and Temporary)\n\nMild burning or stinging sensation on instillation\nTemporary blurred vision\nEye redness\nEye discomfort or itching\n\nLess Common / Serious (Consult Your Doctor Promptly)\n\nPersistent or worsening eye pain\nDelayed corneal healing\nRare corneal complications, including corneal thinning or perforation with prolonged/inappropriate use\nIncreased risk of bleeding at the ocular surface in susceptible individuals\nSigns of an allergic reaction (swelling, itching, rash)\n\nDiscontinue and contact your ophthalmologist immediately if any serious or persistent symptom develops.\n\nComparison: Bromfenac vs. Other Post-Surgical Anti-Inflammatory Options\nTreatmentClassDosing FrequencyKey ConsiderationBromfenac ophthalmic solution 0.09%NSAIDOnce dailyConvenient dosing; no IOP risk; rare corneal risk with prolonged usePrednisolone acetateCorticosteroidMultiple times dailyEffective anti-inflammatory; carries IOP and cataract risk with prolonged useKetorolac ophthalmic solutionNSAIDMultiple times dailySimilar NSAID mechanism; more frequent dosing than bromfenacNepafenac ophthalmic suspensionNSAID (prodrug)1–3 times daily depending on formulationAlternative NSAID option; dosing varies by strength\n\nKey Statistics (Placeholder — Pending Clinical Reviewer Verification)\nMetricValueReported reduction in post-operative cystoid macular edema incidence with prophylactic NSAID use[Placeholder – insert verified clinical trial statistic]Typical duration of post-cataract-surgery bromfenac therapy[Placeholder – insert verified reference range]Reported rate of corneal adverse events with appropriate short-course use[Placeholder – insert epidemiological reference]\nAll statistics above are placeholders and must be verified and populated by a qualified clinical reviewer prior to publication.\n\nExpert Insight\n\n[Placeholder — Expert quote pending. To be added only after review and approval by a licensed ophthalmologist/medical reviewer associated with Steris Healthcare. Do not fabricate or publish without sign-off.]\n\n\nPrice of Bromfenac Ophthalmic Solution 0.09% w/v\nThe price of bromfenac ophthalmic solution 0.09% w/v varies depending on brand, pack size, and region. For current pricing, availability, and prescription verification, please consult your ophthalmologist or an authorized pharmacy.\nPrescription only – consult your doctor.\n\nConclusion\nBromfenac ophthalmic solution 0.09% w/v has become a widely used part of modern post-cataract-surgery care, offering effective pain and inflammation control along with a meaningful reduction in the risk of post-operative cystoid macular edema — all with the convenience of once-daily dosing. As an NSAID rather than a steroid, it avoids the intraocular pressure concerns associated with corticosteroid therapy, though it carries its own specific precautions, particularly around rare corneal complications with prolonged or inappropriate use. Used exactly as directed by your ophthalmic surgeon, within the prescribed post-operative window, bromfenac supports a smoother, more comfortable surgical recovery.\n\nFrequently Asked Questions\n\n1. What is bromfenac ophthalmic solution 0.09% used for?\nIt is used to treat pain and inflammation following cataract surgery and to help reduce the risk of post-operative cystoid macular edema, a swelling of the central retina that can occur after eye surgery.\n\n2. Is bromfenac a steroid?\nNo. Bromfenac is a non-steroidal anti-inflammatory drug (NSAID). It works by inhibiting the cyclooxygenase (COX) enzyme rather than acting through the steroid pathway, and it does not carry the intraocular pressure risks associated with corticosteroids.\n\n3. How often should bromfenac eye drops be used?\nBromfenac ophthalmic solution 0.09% is typically used once daily in the operated eye, making it more convenient than many other post-surgical eye drops that require multiple daily doses.\n\n4. How long is bromfenac used after cataract surgery?\nThe duration is determined by your ophthalmic surgeon based on your individual recovery, often continuing through a defined post-operative period as part of your overall surgical care protocol.\n\n5. Can bromfenac be used with steroid eye drops?\nYes, bromfenac is often prescribed alongside corticosteroid and/or antibiotic eye drops as part of a comprehensive post-surgical regimen, with applications spaced as directed by your doctor.\n\n6. What are the side effects of bromfenac eye drops?\nCommon side effects include mild burning or stinging upon application, temporary blurred vision, and eye redness. Rare but serious effects can include delayed corneal healing or corneal complications with prolonged or inappropriate use.\n\n7. Does bromfenac raise eye pressure?\nNo, as an NSAID, bromfenac does not typically raise intraocular pressure the way corticosteroid eye drops can, which is one of its key advantages in post-surgical care.\n\n8. Can bromfenac cause corneal problems?\nRare but serious corneal complications, including delayed healing or corneal thinning, have been reported with prolonged or inappropriate NSAID use. Any unusual eye pain or vision change should be reported to your doctor immediately.\n\n9. Is bromfenac safe for people on blood thinners?\nNSAIDs like bromfenac can affect bleeding tendency, so patients on blood-thinning medications or with known bleeding disorders should inform their doctor before starting treatment.\n10. Can contact lenses be worn while using bromfenac?\nIt is generally advised to avoid wearing contact lenses during the post-operative treatment period unless your ophthalmologist specifically advises otherwise.\n11. What happens if I miss a dose of bromfenac?\nApply the missed dose as soon as you remember, unless it is nearly time for your next scheduled dose, in which case skip the missed dose. Do not double up doses.\n12. How is bromfenac different from ketorolac eye drops?\nBoth are NSAIDs with a similar mechanism of action, but bromfenac typically requires only once-daily dosing, while ketorolac usually requires multiple applications per day.\n13. Can bromfenac prevent macular edema after cataract surgery?\nBromfenac is commonly used prophylactically around the time of cataract surgery to help reduce the risk of post-operative cystoid macular edema, a recognized complication of intraocular surgery.\n\n14. Is bromfenac safe for long-term use?\nBromfenac is generally prescribed for a defined post-operative course rather than continuous long-term use, and prolonged or unsupervised use should be avoided due to rare corneal risks.\n\n15. Who should not use bromfenac eye drops?\nPatients with known hypersensitivity to bromfenac or other NSAIDs, or those with certain pre-existing corneal or bleeding conditions, should use bromfenac only under close medical supervision, if at all.\n\n16. Does bromfenac cause blurred vision?\nTemporary blurred vision can occur immediately after instillation in some patients and usually resolves quickly. Persistent blurred vision should be reported to your doctor.\n\n17. Can bromfenac be used before cataract surgery as well as after?\nYes, bromfenac is often started shortly before surgery and continued through the post-operative recovery period, following the specific schedule set by your ophthalmic surgeon.\n", "price": 195.0, "discountamount": 136.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2472, "imageuri": "https://productimages.withfloats.com/actual/6a50b1b32d7a16f0f95be110.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a50b1b32d7a16f0f95be110.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-07-10T08:47:42.715Z", "updatedon": "2026-07-10T08:47:42.715Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//bromfenac-ophthalmic-solution-0-09-w-v/2472", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CIPVISION BROMAXIS 0.09%", "category": "Opthalmology Range", "tags": [ "Bromfenac Ophthalmic Solution 0.09% w/v", "bromfenac ophthalmic solution 0.09%" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }